Suppr超能文献

COVID-19 相关呼吸衰竭患者清醒俯卧位治疗:系统评价和荟萃分析。

Awake prone positioning for patients with COVID-19-related respiratory failure: a systematic review and meta-analysis.

机构信息

Internal, Vascular and Emergency Medicine-Stroke Unit, University of Perugia, Perugia, Italy.

出版信息

Intern Emerg Med. 2024 Jan;19(1):147-158. doi: 10.1007/s11739-023-03434-1. Epub 2023 Oct 5.

Abstract

The role of awake prone positioning (aPP) in patients with acute hypoxemic respiratory failure is debated. We performed a systematic review and meta-analysis to evaluate the role of aPP in acute respiratory failure related to COronaVIrus Disease-19 (COVID-19). Studies reporting on the clinical course of patients with acute respiratory failure related to COVID-19 treated or not treated by aPP were included in the systematic review and meta-analysis (ProsperoID: CRD42022333211). The primary study outcome was the composite of in-hospital death or orotracheal intubation; the individual components of the primary outcome were secondary study outcomes. The composite of in-hospital death or orotracheal intubation was available for 6 studies (1884 patients), five randomized and one prospective; a significant reduction in the risk of this outcome was observed in patients treated vs. not treated by aPP (33.5% vs. 39.8%; OR 0.73, 95% CI 0.60-0.89; I 0%). In-hospital death was reported in 34 studies (6808 patients) and occurred in 17.4% vs. 23.5% of patients treated or not treated with aPP (random effect OR 0.60, 95% CI 0.46-0.79; I 59%); orotracheal intubation was observed in 25.8% vs. 32.7% of patients treated or not treated with aPP (27 studies, 5369 patients; random effect OR 0.85, 95% CI 0.56-1.27; I 84%). aPP reduces the risk for death or orotracheal intubation in patients with acute respiratory failure related to COVID-19. Further studies should be conducted to confirm the clinical benefit of aPP outside the ICU.Registration Prospero ID: CRD42022333211.

摘要

清醒俯卧位(aPP)在急性低氧性呼吸衰竭患者中的作用存在争议。我们进行了系统评价和荟萃分析,以评估 aPP 在与 COVID-19 相关的急性呼吸衰竭中的作用。纳入的研究报告了与 COVID-19 相关的急性呼吸衰竭患者的临床病程,这些患者接受或未接受 aPP 治疗。系统评价和荟萃分析(Prospero ID:CRD42022333211)。主要研究结局是院内死亡或经口气管插管的复合结局;主要结局的各个组成部分是次要研究结局。6 项研究(1884 例患者)报告了院内死亡或经口气管插管的复合结局,其中 5 项为随机研究,1 项为前瞻性研究;与未接受 aPP 治疗的患者相比,接受 aPP 治疗的患者的这种结局风险显著降低(33.5%比 39.8%;OR 0.73,95%CI 0.60-0.89;I 0%)。34 项研究(6808 例患者)报告了院内死亡,接受或未接受 aPP 治疗的患者分别为 17.4%和 23.5%(随机效应 OR 0.60,95%CI 0.46-0.79;I 59%);25.8%和 32.7%的患者接受或未接受 aPP 治疗时需要气管插管(27 项研究,5369 例患者;随机效应 OR 0.85,95%CI 0.56-1.27;I 84%)。aPP 可降低与 COVID-19 相关的急性呼吸衰竭患者的死亡或经口气管插管风险。应进一步开展研究以确认 ICU 外 aPP 的临床获益。注册 Prospero ID:CRD42022333211。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1a9/10827908/0032a4552363/11739_2023_3434_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验